Institutional members access full text with Ovid®

Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial

Jeon, Hong Jina,b,c; Fava, Maurizioc; Mischoulon, Davidc; Baer, Leec; Clain, Alisabetc; Doorley, Jamesc; DiPierro, Moneikac; Cardoos, Amberc; Papakostas, George I.c

International Clinical Psychopharmacology: November 2014 - Volume 29 - Issue 6 - p 332–338
doi: 10.1097/YIC.0000000000000039
Original Articles

The aim of this study was to evaluate efficacy of ziprasidone monotherapy for major depressive disorder (MDD) with and without psychomotor symptoms. In accordance with the sequential parallel comparison design, 106 MDD patients (age 44.0±10.7 years; female, 43.4%) were recruited and a post-hoc analysis was carried out on 12-week double-blind treatment with either ziprasidone (40–160 mg/day) or placebo, divided into two phases of 6 weeks each to the assigned treatment sequences, drug/drug, placebo/placebo, and placebo/drug. Psychomotor symptoms were evaluated on the basis of the Mini-International Neuropsychiatric Interview at baseline. Efficacy assessments, on the basis of the 17-item Hamilton Depression Rating Scale (HDRS-17) and the Quick Inventory of Depressive Symptomatology Scale, Self-Rated (QIDS-SR), were performed every week throughout the trial. In phase I, ziprasidone monotherapy produced significant improvement in patients with psychomotor symptoms compared with placebo on the basis of HDRS-17 (F=5.95, P=0.017) and QIDS-SR (F=5.26, P=0.025) scores, whereas no significant changes were found in HDRS-17 (F=2.32, P=0.15) and QIDS-SR (F=3.70, P=0.074) scores in patients without psychomotor symptoms. In phase II, ziprasidone monotherapy produced no significant differences compared with placebo. In the pooled analysis, ziprasidone monotherapy showed significance according to QIDS-SR (Z=2.00, P=0.046) and a trend toward statistical significance according to the HDRS-17 (Z=1.66, P=0.10) in patients with psychomotor symptoms. Ziprasidone monotherapy may produce significant improvement compared with placebo in MDD patients with psychomotor symptoms.

aDepartment of Psychiatry, Depression Center, Samsung Medical Center, Sungkyunkwan University School of Medicine

bSamsung Advanced Institute for Health Sciences & Technology (SAIHST), Seoul, Korea

cDepression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

Correspondence to Hong Jin Jeon, MD, PhD, Department of Psychiatry, Depression Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, #50 Irwon-dong, Gangnam-gu, Seoul 135-710, South Korea Tel: +82 2 3410 3586; fax: +82 2 3410 0050; e-mail: jeonhj@skku.edu

Received October 28, 2013

Accepted March 18, 2014

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins